HT-29 Metastatic Tumor Model Service for Colon Cancer

The HT-29 metastatic tumor model is a well-established preclinical platform for colorectal cancer that supports both routine flank xenografts and organ-directed formats—including cecal orthotopic implantation and splenic injection leading to liver metastasis—in immunodeficient hosts. Alfa Cytology runs HT-29 metastasis programs from authenticated cell preparation through surgical implantation, scheduled imaging, and quantitative readouts covering both primary tumors and metastatic lesions.

Overview of HT-29 Metastatic Tumor Model for Colon Cancer

HT-29 was established in 1964 by Fogh and Trempe from a primary colorectal adenocarcinoma resected from a 44-year-old woman, making it one of the oldest continuously cultured human cancer lines and the workhorse of the original HT series. The cells grow as adherent monolayers with glandular, epithelial features and carry a molecular profile that remains distinctive among colorectal models: KRAS, NRAS, PTEN, and EGFR are wild-type, while BRAF carries the pathogenic V600E substitution and TP53, APC, PIK3CA, and SMAD4 are mutated. With microsatellite-stable, CIMP-positive, CMS3 character, plus strong expression of COX-2, FAP, integrin-α6, and CXCR4, HT-29 has become a standard substrate for EGFR-antibody evaluation in a KRAS wild-type background and for BRAF-inhibitor studies.

Fig 1. Phenotypic and molecular comparison of EMT markers between recellularized scaffolds and HT-29 cells cultured in 2D. (D’angelo, Edoardo, et al., 2020)

For metastasis work, the model’s value lies in its organ-directed formats. Splenic injection of 5 × 10⁵ to 1 × 10⁶ cells sends tumor cells through the portal circulation and produces liver metastases within two to three weeks, and serial passage through that route yielded CX-1, a liver-tropic derivative; repeated rounds of splenic selection have generated similarly enriched subclones from other lines, and the same logic applies to HT-29. Cecal-wall implantation—5 × 10⁵ luciferase-tagged cells injected between mucosa and muscularis—recapitulates lymphatic, hematogenous, and coelomic dissemination, with HT-29 among the lines most prone to lymph-node involvement in comparative orthotopic studies. Intracardiac injection seeds bone marrow, and imaging suites built around bioluminescence, MRI, GFP or RFP fluorescence, and PET confirmation allow each of these patterns to be quantified longitudinally. Chemotherapy benchmarking is straightforward, with 5-FU sensitivity documented across formats.

Cell Line Information: HT-29

Culture of HT-29 is straightforward once established: McCoy’s 5a medium with 10% fetal bovine serum at 37 °C in a 5% CO₂ atmosphere, with splits of 1:3 to 1:8 every two to four days and harvest at 70–80% confluence. The line’s documented STR profile makes misidentification easy to detect, an important safeguard for a culture in service for six decades. Inoculum quality drives take rates in every implantation format, so pre-implantation checks—viability, mycoplasma status, and short-passage expansion—are standard practice before any animal receives cells.

Our Services

Colorectal metastasis studies demand surgical precision and quantitative discipline, and Alfa Cytology builds both into every HT-29 engagement: implantation surgeries follow standardized operative protocols, imaging schedules are fixed in advance, and metastatic burden is scored under pre-defined rules rather than ad hoc judgment. Sponsors receive integrated packages pairing in vitro drug profiling with in vivo efficacy data, histopathology, and complete imaging archives.

Workflow of HT-29 Metastatic Tumor Model Construction

HT-29 metastasis studies combine cell preparation, survival surgery, and scheduled imaging in a fixed order. The sequence below reflects the most commonly requested configurations; each stage is adjusted to the sponsor’s route and endpoint requirements.

1. Cell authentication and banking: HT-29 stocks undergo STR identity verification and mycoplasma clearance before in vitro expansion in McCoy’s 5a medium, with passage history recorded for every vial.
2. Surgical planning: The metastatic route is selected—flank, cecal-wall orthotopic, intrasplenic, or intracardiac—and operative approaches, anesthesia plans, and post-recovery criteria are documented before any procedure.
3. Implantation: Flank implants receive 5 × 10⁶ cells in 100–200 µL PBS/Matrigel; cecal-wall or intrasplenic delivery uses 5 × 10⁵ to 1 × 10⁶ cells under sterile surgical conditions, with the injection site sealed to prevent leakage.
4. Post-operative recovery and imaging baseline: Animals recover under observation, and luciferase-tagged cohorts receive baseline bioluminescence imaging, with MRI substituted where soft-tissue detail is required.
5. Randomization and treatment: Animals are distributed across vehicle, benchmark (such as 5-FU), and investigational arms based on tumor volume or photon flux; dosing follows the sponsor-defined regimen.
6. Scheduled monitoring: Caliper, bioluminescence, or MRI readouts are captured on the predefined cadence, alongside body-weight and clinical-status checks with humane endpoints enforced.
7. Necropsy and metastasis scoring: Primary tumors are excised and weighed; livers, lymph nodes, and distant organs are inspected and scored for lesions under pre-registered criteria; histology, IHC, and molecular endpoints are finalized, and the quantitative study report is delivered.

Fig 2. HT-29 Metastatic Tumor Model construction workflow.

Case Study-HT-29 Metastatic Tumor Model Development

Alfa Cytology has conducted HT-29 metastasis programs spanning splenic-injection liver-metastasis studies with MRI or bioluminescence quantification, cecal orthotopic models assessing lymph-node and peritoneal spread, and flank xenograft work supporting targeted-agent evaluation in KRAS wild-type backgrounds, with combination responses confirmed in vivo. Readouts across these studies have included primary tumor growth curves, metastatic lesion counts and volumes, survival, and histopathological confirmation of lesion identity; representative datasets can be discussed once confidentiality terms are agreed.

Why Choose Alfa Cytology?

Metastatic colorectal work rewards teams that can combine cell culture, survival surgery, and quantitative imaging without gaps. Alfa Cytology unifies those capabilities under a single project structure.

• Surgical capability: cecal-wall, splenic, and hepatic implantation procedures performed by experienced operators.
• Imaging options: bioluminescence, MRI, and fluorescence readouts matched to each study design.
• Defined scoring rules: metastatic lesions quantified under pre-registered criteria for reproducibility.
• Molecularly characterized substrate: documented mutation profile (KRAS wild-type, BRAF V600E) supports targeted-therapy rationales.
• Quality inputs: STR-authenticated, mycoplasma-free cells with controlled passage history.
• Complete reporting: imaging archives, raw data, and statistics-ready summaries accompany every study.

Contact Us

Looking to test a candidate against colorectal metastasis? Contact us to review the HT-29 formats that match your program—flank, cecal orthotopic, or splenic liver-metastasis—and receive a proposed design with timelines. Alfa Cytology is ready to help; reach out today.

For research use only. Not intended for any clinical use.